Drugs / SHR-1702
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04443751 | Sep 2020 → Feb 2023 | acute myeloid leukemia, myelodysplastic syndrome | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03871855 | Apr 2019 → Jun 2021 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03871855 ↗ |
| Route | Intravenous | “Administered IV” NCT03871855 ↗ |